Curis/CRIS

$15.22

-4.57%
-
1D1W1MYTD1YMAX

About Curis

Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). Its other clinical programs include Fimepinostat and CA-170. Fimepinostat is an oral, dual inhibitor of histone deacetylase (HDAC), and phosphotidyl-inositol 3 kinase (PI3K) enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target V-domain Ig Suppressor of T-cell Activation (VISTA) and PDL1 immune checkpoint proteins.

Ticker

CRIS

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

James Dentzer

Employees

48

Headquarters

Lexington, United States

Curis Metrics

BasicAdvanced
$85.82M
Market cap
-
P/E ratio
-$9.02
EPS
3.63
Beta
-
Dividend rate
$85.82M
3.63398
$20.00
$3.80
36.62K
4.506
-50.95%
-143.19%
-58.32%
8.562
4.363
8.029
-1.37%
25.9%
-2.56%

What the Analysts think about Curis

Analyst Ratings

Majority rating from 6 analysts.
Buy

Price Targets

Average projection from 4 analysts.
42.9% upside
High $26.00
Low $15.00
$15.22
Current price
$21.75
Average price target

Curis Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-450% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$2.6M
-7.14%
Net income
$-11.7M
-3.31%
Profit margin
-450%
4.13%

Curis Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 3.97%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$2.40
-$2.40
-$2.13
-$2.03
-
Expected
-$2.08
-$2.36
-$2.33
-$2.11
-$2.12
Surprise
15.38%
1.69%
-8.43%
-3.97%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Curis stock?

Curis (CRIS) has a market cap of $85.82M as of April 19, 2024.

What is the P/E ratio for Curis stock?

The price to earnings (P/E) ratio for Curis (CRIS) stock is 0 as of April 19, 2024.

Does Curis stock pay dividends?

No, Curis (CRIS) stock does not pay dividends to its shareholders as of April 19, 2024.

When is the next Curis dividend payment date?

Curis (CRIS) stock does not pay dividends to its shareholders.

What is the beta indicator for Curis?

Curis (CRIS) has a beta rating of 3.63. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Curis stock price target?

The target price for Curis (CRIS) stock is $21.75, which is 42.9% above the current price of $15.22. This is an average based on projections from 4 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Curis stock

Buy or sell Curis stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing